Kura Oncology (KURA) EBITDA Margin (2025 - 2026)
Kura Oncology (KURA) posted quarterly EBITDA Margin of 431.51% for Q1 2026, up 2710.0% year-over-year from 15.36% in Q1 2025, and up 7.17% quarter-over-quarter from 464.82% in Q4 2025.
Kura Oncology (KURA) EBITDA Margin (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported EBITDA Margin for 2 consecutive years, with 431.51% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 2710.0% year-over-year to 431.51%; the TTM figure through Mar 2026 stood at 382.57% (changed N/A YoY), while the FY2025 annual figure was 449.94%, down 9140.0% from the prior year.
- EBITDA Margin advanced to 431.51% in Q1 2026 per KURA's latest filing, from 464.82% in the prior quarter.
- Across five years, EBITDA Margin topped out at 268.54% in Q2 2025 and bottomed at 464.82% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | -349.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -349.77% |
| Mar 31, 2026 | -431.51% |
| Dec 31, 2025 | -464.82% |
| Sep 30, 2025 | -354.78% |
| Jun 30, 2025 | -268.54% |
| Mar 31, 2025 | -458.61% |